Fachiroh J, Stevens SJ, Haryana SM, et al. Combination of Epstein-virus scaffold（BDRF1/VCA-p40）and small capsid protein（BFRF3/VCA-p18）into a single molecule for imprived serodiagnosis of acute and malignant EBV-driven disease[J]. J Virol Methods, 2010, 169（1）, 79-86.
Feederle R, Kost M, Baumann M, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators[J]. EMBO J, 2000, 19（12）：3080-3089.
Islam MS, Anoop P, Gordon-Smith EC, et al. Epstein-Barr virus infections after allogeneic stem cell transplantation A comparison between nonmalignant and malignant hematological disorder[J]. Hematology, 2010, 15（5）：344-350.
[7]
Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma[J]. Cancer, 2003, 105（5）：706-709.
[8]
Paramita DK, Fachiroh J, Artama WT, et al. Native early antigen of Epstein-Barr virus a promissing antigen for diagnosis of nasopharyngeal carcinoma[J]. J Med Virol, 2007, 79（11）：1710-1721.
[9]
Dardari R, Hinderer W, Lang D, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients：Complementary test of ZEBRA protein and early antigens p54 and p138[J]. J Clin Micro, 2001, 39（9）：3164-3169.
[10]
Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma[J]. Int J Cancer, 2003, 105（4）：706-709.
[11]
Chan JKC, Pilch BZ, Bray F, et al. Nasopharyngeal carcinoma[M] //Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Orga-nization Classification of Tumours. Pathology&Genetics. Head and Neck Tumours. Lyon France：IARC-Press, 2005：85-97.
[12]
Allen MD, Young LS, Dawson CW. The Epstein-virus encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility[J]. Virol, 2005, 79（6）：1789-1802.
